Genome Medicine | Volume 1 Issue 9

Advanced Search

Submit a manuscript Register Follow us on

Follow us on Twitter

Explore journal

Advertisement

Advertisement

Articles

cover

		Volume 1 Issue 9
		Comment
		Commentary Gene patents and personalized medicine - what lies ahead? Subhashini Chandrasekharan, Robert Cook-Deegan Genome Medicine 2009, 1:92 (28 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The odds are increasing that government policy will foster socially beneficial uses of genetic testing while preserving intellectual property incentives and mitigating the problems that arise from legal monopolies.
		Commentary Human population structure, genome autozygosity and human health Harry Campbell, Igor Rudan, Alan H Bittles, Alan F Wright Genome Medicine 2009, 1:91 (28 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The transition of population structure from rural endogamous communities to large, increasingly panmictic, urban populations is predicted to increase outbreeding and reduce the burden of recessively inherited disorders.
		Musings Musings on genome medicine: the Obama effect redux David G Nathan, Stuart H Orkin Genome Medicine 2009, 1:86 (11 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genome Medicine’s commentators throw their support behind Francis Collins and discuss how the next few months of the Obama administration will be crucial for the future of genome medicine research.
		Review
		Minireview MicroRNA and vascular smooth muscle cell phenotype: new therapy for atherosclerosis? Chunxiang Zhang Genome Medicine 2009, 1:85 (9 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Micro-RNAs, particularly miR-145, may represent new therapeutic targets for the treatment of atherosclerosis.
		Review Parasite-host interaction in malaria: genetic clues and copy number variation Imad Faik, Elisandra de Carvalho, Jürgen FJ Kun Genome Medicine 2009, 1:82 (2 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Our understanding of genetic variation in both parasite and host can lead to improved monitoring of drug resistance, personalized adjustment of medication dosing, and possibly even gene replacement therapy.
		Review How genomics has informed our understanding of the pathogenesis of osteoporosis Mark L Johnson, Nuria Lara, Mohamed A Kamel Genome Medicine 2009, 1:84 (7 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Improved understanding of the genetics and biology driving the pathophysiology of osteoporosis facilitates development of new and effective treatment to combat and possibly cure this disease.
		Review ChIP'ing the mammalian genome: technical advances and insights into functional elements Eleanor Wong, Chia-Lin Wei Genome Medicine 2009, 1:89 (23 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Chromatin immunoprecipitation assays, together with genome-wide analyses, allow an unbiased and comprehensive view of transcriptional control, epigenetic regulation and chromatin structures.
		Review Network strategies to understand the aging process and help age-related drug design Gábor I Simkó, Dávid Gyurkó, Dániel V Veres, Tibor Nánási, Peter Csermely Genome Medicine 2009, 1:90 (28 September 2009) Abstract \| Full text \| PDF \| PubMed \| 2 comments \| Editor’s summary Protein-protein interaction networks are highly appropriate tools for understanding the extreme complexity of the aging process and suggest that multi-target drugs may become especially useful for treating age-related diseases.
		Research
		Research Networking of differentially expressed genes in human cancer cells resistant to methotrexate Elisabet Selga, Carlota Oleaga, Sara Ramírez, M Cristina de Almagro, Véronique Noé, Carlos J Ciudad Genome Medicine 2009, 1:83 (4 September 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Dikkopf homolog-1, UDP-glucuronosyltransferase 1A and Eukaryotic translation elongation factor 1 alpha 1 play key roles in the development of resistance to methotrexate and offer novel therapeutic targets for chemosensitization to cancer therapy.
		Correspondence
		Correspondence Bridging the gap between systems biology and medicine Gilles Clermont, Charles Auffray, Yves Moreau, David M Rocke, Daniel Dalevi, Devdatt Dubhashi, Dana R Marshall, Peter Raasch, Frank Dehne, Paolo Provero, Jesper Tegner, Bruce J Aronow, Michael A Langston, Mikael Benson Genome Medicine 2009, 1:88 (29 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The translation of data generated by systems biology approaches into the clinic generates a series of unique questions and challenges, and should be driven by the collaboration of clinical, experimental, and computational scientists.
		Correspondence Planning for translational research in genomics Naomi Hawkins, Jantina de Vries, Paula Boddington, Jane Kaye, Catherine Heeney Genome Medicine 2009, 1:87 (29 September 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Careful planning during the early stages of a genomic research project will ensure the smooth translation of research findings into the clinic, even for projects whose immediate benefit is not apparent.

Advertisement

Advertisement